Lead Product(s) : Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : ViiV Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
ACTG Launches Tuberculosis Drug Interaction Trial Among HIV Patients
Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.
Brand Name : Tivicay
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2024
Lead Product(s) : Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : ViiV Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment
Details : Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price for the treatment of tuberculosis.
Brand Name : Rifapentine/Isoniazid-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 07, 2022
Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
